IP Library Granted Patent US 12709757
Granted Patent B2
US 12709757 · App. 18/805,564 · Granted Aug 18, 2026

Production of milk oligosaccharides in plants

Inventors: Patrick M. Shih (Berkeley, CA); Collin Robert E. Barnum (Berkeley, CA)
Assignee: The Regents of the University of California
C12N15/8243C12N15/52C12N9/1051C12N9/88C12Y204/01069C12Y204/01274C12Y402/01047
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12709757
App. No.
18/805,564
Granted
Aug 18, 2026
Kind
B2
Abstract

Mammalian milk oligosaccharides (MMO) are produced in plants engineered to express recombinant MMO biosynthetic pathways.

Claims (38)

1 . A method of producing a mammalian milk oligosaccharide (MMO) in a plant or plant part, comprising growing a plant comprising and expressing a recombinant MMO biosynthetic pathway sufficient to produce the MMO, wherein the pathway produces the MMO in the plant or plant part, wherein the pathway comprises recombinant enzymes:

a β1-4 galactosyltransferase (β1-4-GalT), which glycosylates glucose using UDP-galactose to make lactose; and

a β1-3 N-acetylglucosaminyltransferase (1-3-GlcNAc), which generates lacto-N-triose (LNTII) through the transfer of GlcNAC from UDP-GlcNAc to the galactose in the lactose; and at least one of:

a β1-3-galactosyltransferase (β1-3-GalT) and a β1-4-galactosyltransferase (β1-4-GalT), which converts the LNTII to lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT), respectively,

wherein the plant is tobacco.

2 . A method of claim 1 , wherein the pathway comprises recombinant enzyme:

a α1-2-fucosyltransferase (α1-2-FucT) to produce lacto-N-fucopentaose I (LNFPI), a fucosylated pentasaccharide generated by the addition of an α-1,2-linked fucose to the terminal galactose in the lacto-N-tetraose (LNT).

3 . The method of claim 1 , wherein the pathway comprises recombinant enzyme:

a α2-3-sialyltransferase or a α2-6-sialyltransferase to add an α-2,6-linked or α-2,3-linked Neu5Ac to the lacto-N-neotetraose (LNnT) to produce sialyllacto-N-neotetraose d (LSTd) or sialyllacto-N-neotetraose c (LSTc), respectively.

4 . The method of claim 1 , wherein the plant is comprising and expressing a eukaryotic or prokaryotic nucleotide sugar biosynthetic pathway sufficient to increase the production of the MMO.

5 . The method of claim 1 , wherein the plant is further comprising and expressing a prokaryotic nucleotide sugar biosynthetic pathway sufficient to increase the production of the MMO, wherein the pathway comprises one, two or three of the following pathways and corresponding enzymes:

a) GDP-fucose pathway and enzymes: ManA, ManB, ManC, Gmd, and WcaG,

b) UDP-galactose pathway and enzymes: pgi, pgm, GalU, and GalE, and

c) UDP-GlcNAc pathway and enzymes: glmS, glmM, and glmU.

6 . The method of claim 1 , wherein the MMO is of a mammal selected from human, cow and goat, preferably wherein the MMO is a human milk oligosaccharide (HMO).

7 . The method of claim 1 , the plant comprising and expressing a plurality of recombinant MMO biosynthetic pathways sufficient to produce a plurality of different MMOs.

8 . The method of claim 1 , wherein:

the β1-4 galactosyltransferase (β1-4-GalT) is GalTPM1141;

the β1-3 N-acetylglucosaminyltransferase (β1-3-GnT) is NmLgtA;

the β1-3-galactosyltransferase (β1-3-GalT) is Cvβ3GalT;

the β1-4-galactosyltransferase (β1-4-GalT) is HP0826 or NmLgtB;

the α1-2-fucosyltransferase (α1-2-FucT) is Te2FT;

the α2-3-sialyltransferase is PmSt3); and

the α2-6-sialyltransferase is St6.

9 . The method of claim 1 , wherein the plant or plant part is comprising and expressing of a β1-4-GalT, a β1-3-GlcNAcT, a β1-4-GalT, and a 1-3-GalT to produce LNnT and LNT.

10 . The method of claim 1 , wherein the plant or plant part is producing non-fucosylated neutral MMOs (nMMOs) comprising a lactose core with decorations of galactose and N-acetylglucosamine (GlcNAc).

11 . The method of claim 1 , wherein the plant or plant part is producing fucosylated MMOs, particularly comprising a lactose core decorated with one or more fucose moieties.

12 . The method of claim 1 , wherein the plant or plant part is comprising and expressing a β1-4-GalT, a β1-3-GlcNAcT, a β1-4-GalT, a β1-3-GalT and a α1-2-fucosyltransferase (α1-2-FucT) to produce lacto-N-fucopentaose I (LNFPI), a fucosylated pentasaccharide generated by the addition of an α-1,2-linked fucose to the terminal galactose in lacto-N-tetraose (LNT).

13 . The method of claim 1 , wherein the plant or plant part is producing fucosyllactose, lacto-N-tetraose or lacto-N-neotetraose, and lacto-N-fucopentaose I.

14 . The method of claim 1 , wherein to improve LNFPI yields, nucleotide sugar biosynthetic pathways ( FIG. 1 B ) are expressed to increase the availability of GDP-fucose, UDP-galactose, and UDP-GlcNAc, combinatorially.

15 . The method of claim 1 , wherein the pathway comprises recombinant enzyme:

a α1-2-fucosyltransferase (α1-2-FucT) to produce lacto-N-fucopentaose I (LNFPI), a fucosylated pentasaccharide generated by the addition of an α-1,2-linked fucose to the terminal galactose in the lacto-N-tetraose (LNT), and

the plant further comprises a prokaryotic GDP-fucose biosynthetic pathway comprising enzymes: ManA, ManB, ManC, Gmd and WcaG.

16 . The method of claim 1 , producing CMP-Neu5Ac.

17 . The method of claim 1 , wherein the plant or plant part is comprising and expressing a three gene bacterial pathway comprising genes: neuA, neuB, and neuC, or a four gene mammalian pathway comprising genes: GNE, NANS, NANP, and CMAS, which utilize UDP-GlcNAc as a precursor for the production of CMP-Neu5Ac.

18 . The method of claim 1 , wherein the plant or plant part is comprising and expressing a mammalian CMP-Neu5Ac pathway, comprising genes: GalTPM1141, NmLgtA, Cvβ3GalT, and Hp0826 for NmLgtB, and either PmSt3 or St6, to produce 3′SL, 6′SL and isomers of LST.

19 . The method of claim 1 , wherein the plant is a stable, transgenic plant, comprising constructs for the constitutive production of 2′FL and LNFPI.

20 . The method of claim 1 , further comprising isolating the MMO from the plant or plant part.